This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | MicrobiomeTrials
← Back to trials NCT02911142
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2017-07-03Est. Completion: 2024-10-01
Enrollment target: 17 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in HIV Kaposi's Sarcoma Lymphomas Multicentric Castleman's Disease Primary Effusion Lymphoma
BACKGROUND:
* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or …
Bethesda, United States
KSHV Inflammatory Cytokine Syndrome (KICS) KSHV HHV-8
Background:
\- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associ…
Bethesda, United States Est. completion Dec 31, 2028
AIDS-Related Diffuse Large B-cell Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8 Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8 Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8 Plasmablastic Lymphoma Primary Effusion Lymphoma
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (ri…
Multiple Locations Est. completion Apr 30, 2028